COMMISSION IMPLEMENTING REGULATION (EU) 2020/421
of 18 March 2020

amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances abamectin, Bacillus subtilis (Cohn 1872) strain QST 713, Bacillus thuringiensis subs. Aizawai strains ABTS-1857 and GC-91, Bacillus thuringiensis subs. Israelensis (serotype H-14) strain AM65-52, Bacillus thuringiensis subs. Kurstaki strains ABTS 351, PB 54, SA 11, SA12 and EG 2348, Beauveria bassiana strains ATCC 74040 and GHA, clodinafop, cyproyralid, Cylida pomonella Granulovirus (CpGV), cyprodinil, dichlorprop-P, fenpyroximate, fosetyl, Lecanicillium muscarium (formerly 'Verticillium lecanii') strain Ve6, mepanipyrim, Metarhizium anisopliae (var. anisopliae) strain BIPESCO 5/F52, metconazole, metrafenone, Phlebiopsis gigantea strains FOC PG 410.3, VRA 1835 and VRA 1984, pirimicarb, Pseudomonas chlororaphis strain MA342, pyrimethanil, Pythium oligandrum M1, ramsulfuron, spinosad, Streptomyces K61 (formerly 'S. griseoviridis'), Trichoderma asperellum (formerly 'T. harzianum') strains ICC012, T25 and TV1, Trichoderma atroviride (formerly 'T. harzianum') strains IMI 206040 and T11, Trichoderma gamsii (formerly 'T. viride') strain ICC080, Trichoderma harzianum strains T-22 and ITEM 908, triclopyr, trinexapac, triticonazole and ziram

(The text with EEA relevance)

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,


Whereas:

(1) Part A of the Annex to Commission Implementing Regulation (EU) No 540/2011 (2) sets out the active substances deemed to have been approved under Regulation (EC) No 1107/2009.

(2) The approval periods of the active substances abamectin, Bacillus subtilis (Cohn 1872) strain QST 713, Bacillus thuringiensis subs. Aizawai strains ABTS 1857 and GC-91, Bacillus thuringiensis subs. Israelensis (serotype H-14) strain AM65-52, Bacillus thuringiensis subs. Kurstaki strains ABTS 351, PB 54, SA 11, SA12 and EG 2348, Beauveria bassiana strains ATCC 74040 and GHA, clodinafop, cyproyralid, Cylida pomonella Granulovirus (CpGV), cyprodinil, dichlorprop-P, fenpyroximate, fosetyl, Lecanicillium muscarium (formerly 'Verticillium lecanii') strain Ve6, mepanipyrim, Metarhizium anisopliae (var. anisopliae) strain BIPESCO 5/F52, metconazole, metrafenone, Phlebiopsis gigantea strains FOC PG 410.3, VRA 1835 and VRA 1984, pirimicarb, Pseudomonas chlororaphis strain MA342, pyrimethanil, Pythium oligandrum M1, ramsulfuron, spinosad, Streptomyces K61 (formerly 'S. griseoviridis'), Trichoderma asperellum (formerly 'T. harzianum') strains ICC012, T25 and TV1, Trichoderma atroviride (formerly 'T. harzianum') strains IMI 206040 and T11, Trichoderma gamsii (formerly 'T. viride') strain ICC080, Trichoderma harzianum strains T-22 and ITEM 908, triclopyr, trinexapac, triticonazole and ziram were extended until 30 April 2020 by Commission Implementing Regulation (EU) 2019/168 (3).

Applications for the renewal of the approval of those substances were submitted in accordance with Commission Implementing Regulation (EU) No 844/2012 (4).

Furthermore, an extension of the approval period is prescribed for the active substances dichlorprop-P, mepanipyrim, spinosad, trinexapac and fosetyl, to allow the necessary time to carry out the assessment relating to endocrine disrupting properties in accordance with the procedure set out in Articles 13 and 14 of Implementing Regulation (EU) No 844/2012.

Due to the fact that the assessment of all those substances has been delayed for reasons beyond the control of the applicants, the approvals of those active substances are likely to expire before a decision has been taken on their renewal. It is therefore necessary to extend their approval periods.

In view of the aim of the first paragraph of Article 17 of Regulation (EC) No 1107/2009, as regards cases where the Commission is to adopt a Regulation providing that the approval of an active substance referred to in the Annex to this Regulation is not renewed because the approval criteria are not satisfied, the Commission is to set the expiry date at the same date as before this Regulation or at the date of the entry into force of the Regulation providing that the approval of the active substance is not renewed, whichever date is later. As regards cases where the Commission is to adopt a Regulation providing for the renewal of an active substance referred to in the Annex to this Regulation, the Commission will endeavour to set, as appropriate under the circumstances, the earliest possible application date.

Implementing Regulation (EU) No 540/2011 should therefore be amended accordingly.

The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Plants, Animals, Food and Feed,

HAS ADOPTED THIS REGULATION:

Article 1

The Annex to Implementing Regulation (EU) No 540/2011 is amended in accordance with the Annex to this Regulation.

Article 2

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 18 March 2020.

For the Commission

The President

Ursula VON DER LEYEN

ANNEX I

Part A of the Annex to Implementing Regulation (EU) No 540/2011 is amended as follows:

(1) in the sixth column, expiration of approval, of row 74, Ziram, the date is replaced by ‘30 April 2021’;

(2) in the sixth column, expiration of approval, of row 89, *Pseudomonas chlororaphis* strain MA 342, the date is replaced by ‘30 April 2021’;

(3) in the sixth column, expiration of approval, of row 90, Mepanipyrim, the date is replaced by ‘30 April 2021’;

(4) in the sixth column, expiration of approval, of row 123, Clodinafop, the date is replaced by ‘30 April 2021’;

(5) in the sixth column, expiration of approval, of row 124, Pirimicarb, the date is replaced by ‘30 April 2021’;

(6) in the sixth column, expiration of approval, of row 125, Rimsulfuron, the date is replaced by ‘30 April 2021’;

(7) in the sixth column, expiration of approval, of row 127, Triconazole, the date is replaced by ‘30 April 2021’;

(8) in the sixth column, expiration of approval, of row 129, Clopyralid, the date is replaced by ‘30 April 2021’;

(9) in the sixth column, expiration of approval, of row 130, Cyprodinil, the date is replaced by ‘30 April 2021’;

(10) in the sixth column, expiration of approval, of row 131, Fosetyl, the date is replaced by ‘30 April 2021’;

(11) in the sixth column, expiration of approval, of row 132, Trinexapac, the date is replaced by ‘30 April 2021’;

(12) in the sixth column, expiration of approval, of row 133, Dichlorprop-P, the date is replaced by ‘30 April 2021’;

(13) in the sixth column, expiration of approval, of row 134, Metconazole, the date is replaced by ‘30 April 2021’;

(14) in the sixth column, expiration of approval, of row 135, Pyrimethanil, the date is replaced by ‘30 April 2021’;

(15) in the sixth column, expiration of approval, of row 136, Triclopyr, the date is replaced by ‘30 April 2021’;

(16) in the sixth column, expiration of approval, of row 137, Metrafenone, the date is replaced by ‘30 April 2021’;

(17) in the sixth column, expiration of approval, of row 138, *Bacillus subtilis* (Cohn 1872) strain QST 713, the date is replaced by ‘30 April 2021’;

(18) in the sixth column, expiration of approval, of row 139, Spinosad, the date is replaced by ‘30 April 2021’;

(19) in the sixth column, expiration of approval, of row 193, *Bacillus thuringiensis* subsp. aizawai strain ABTS-1857 and strain GC-91, the date is replaced by ‘30 April 2021’;

(20) in the sixth column, expiration of approval, of row 194, *Bacillus thuringiensis* subsp. israelensis (serotype H-14) strain AM63-52, the date is replaced by ‘30 April 2021’;

(21) in the sixth column, expiration of approval, of row 195, *Bacillus thuringiensis* subsp. kurstaki strain ABTS 351, strain PB 54, strain SA 11, strain SA 12, strain EG 2348, the date is replaced by ‘30 April 2021’;

(22) in the sixth column, expiration of approval, of row 197, *Beauveria bassiana* strain ATCC 74040, strain GHA, the date is replaced by ‘30 April 2021’;

(23) in the sixth column, expiration of approval, of row 198, *Cydia pomonella* Granulovirus (CpGV), the date is replaced by ‘30 April 2021’;

(24) in the sixth column, expiration of approval, of row 199, *Lecanicillium muscarium* (formerly *Verticillium lecanii*) strain Ve 6, the date is replaced by ‘30 April 2021’;

(25) in the sixth column, expiration of approval, of row 200, *Metahrizium anisopliae* var. anisopliae (formerly *Metahrizium anisopliae*) strain BIPESCO 5/F52, the date is replaced by ‘30 April 2021’;

(26) in the sixth column, expiration of approval, of row 201, *Phlebiopsis gigantea* strain VRA 1835, strain VRA 1984, strain FOC PG 410.3, the date is replaced by ‘30 April 2021’;

(27) in the sixth column, expiration of approval, of row 202, *Pythium oligandrum* strain M1, the date is replaced by ‘30 April 2021’;
(28) in the sixth column, expiration of approval, of row 203, Streptomyces K61 (formerly S. griseoviridis) strain K61, the date is replaced by ‘30 April 2021’;

(29) in the sixth column, expiration of approval, of row 204, Trichoderma atroviride (formerly T. harzianum) strains IMI206040 and T11, the date is replaced by ‘30 April 2021’;

(30) in the sixth column, expiration of approval, of row 206, Trichoderma harzianum Rifai strain T-22, strain ITEM 908, the date is replaced by ‘30 April 2021’;

(31) in the sixth column, expiration of approval, of row 207, Trichoderma asperellum (formerly T. harzianum) strain ICC012, strain T25, strain TV1, the date is replaced by ‘30 April 2021’;

(32) in the sixth column, expiration of approval, of row 208, Trichoderma gamsii (formerly T. viride) strain ICC080, the date is replaced by ‘30 April 2021’;

(33) in the sixth column, expiration of approval, of row 210, Abamectin, the date is replaced by ‘30 April 2021’;

(34) in the sixth column, expiration of approval, of row 213, Fenpyroximate, the date is replaced by ‘30 April 2021’.